Medtronic, Inc. today announced the U.S. Food & Drug Administration (FDA) approval of its AdaptiveStim(TM) with RestoreSensor(TM) neurostimulation system, the first chronic pain treatment of its kind. This new technology functions much like neurostimulation devices of the past, but their shortfall was that when the patient changed positions they would have to manually adjust the amount of stimulation because the distance between the device and their spine would change. The new AdaptiveStim device utilizes the same motion sensor technology found in video games and smartphones to automatically adjust to position changes, increasing the patients quality of life.
